Eileen E. Parkes, Steven M. Walker, Laura E. Taggart, Nuala McCabe et al.
Background: Previously we identified a DNA damage response-deficient (DDRD) molecular subtype within breast cancer. A 44-gene assay identifying this subtype was validated as predicting benefit from DNA-damaging chemotherapy. This subtype was defined by interferon signaling. In this study, we address...
Nuala McCabe, Conor Hanna, Steven M. Walker, David Gonda et al.
Ataxia telangiectasia mutated (ATM) is an important signaling molecule in the DNA damage response (DDR). ATM loss of function can produce a synthetic lethal phenotype in combination with tumor-associated mutations in FA/BRCA pathway components. In this study, we took an siRNA screening strategy to i...
Paula M. Gilmore, Nuala McCabe, Jennifer E. Quinn, Richard D. Kennedy et al.
BRCA1 has been implicated in a number of cellular processes, including transcriptional regulation, DNA damage repair, cell cycle arrest, and apoptosis. We identified mitogen-activated protein kinase (MAPK) kinase kinase 3 (MEKK3), an upstream regulator of the c-Jun NH(2)-terminal kinase/stress-activ...
Nuala McCabe, Kevin M. Prise, Richard D. Kennedy
The phosphatase and tensin homologue, PTEN, was identified in 1997 and later found to be frequently disrupted in multiple sporadic tumour types and targeted by germline mutations in patients with cancer predisposition syndromes such as Cowden disease [1]. The principal catalytic function of PTEN is ...
Nuala McCabe, Steven M. Walker, Caroline Greenan, Katarina Wikström et al.
Abstract Introduction: The tumour suppressor PTEN is frequently lost in multiple cancer types, loss of PTEN function has been linked to activation of the AKT signalling pathway. The regulation of the AKT signalling has long been attributed as the key tumour suppressing function of PTEN. However, it ...